Previous 10 | Next 10 |
Shares of Arcturus Therapeutics (NASDAQ: ARCT) were soaring 34.7% higher as of 10:56 a.m. EDT on Tuesday. The big jump came after the company announced that Singapore regulators approved the advancement of two messenger RNA COVID-19 vaccine candidates into phase 1/2 clinical testing...
Gainers: Arcturus Therapeutics ARCT +35%, Translate Bio TBIO +29%, Flora Growth (NASDAQ:FLGC) +27%, Lixte Biotechnology (NASDAQ:LIXT) +27%, Outlook Therapeutics (NASDAQ:OTLK) +23%. Losers: Neuronetics STIM -39%, Bright Health BHG -19%,...
Arcturus Therapeutics (NASDAQ:ARCT) has received approval for a Clinical Trial Application (CTA) from the Singapore Health Sciences Authority (HSA) to enable the advancement of two STARR mRNA vaccine candidates into the clinic. Shares of the company up nearly 7% premarket. The Phase...
Singapore is the second country to approve the advancement of ARCT-154 into clinical development ARCT-154 and ARCT-165 elicit high levels of neutralizing antibodies in non-human primates against multiple variants of concern Arcturus Therapeutics Holdings Inc. (the ...
The Phase 1/2/3 trial to be funded and sponsored by Arcturus’ manufacturing partner Vinbiocare ARCT-154 to be developed in parallel with ARCT-021, Arcturus’ lead investigational COVID-19 vaccine Arcturus Therapeutics Holdings Inc. (the “Company...
Arcturus Therapeutics Holdings (NASDAQ:ARCT) announces an agreement with Vinbiocare Biotechnology Joint Stock Company regarding a collaboration to establish a manufacturing facility in Vietnam for the manufacture of Arcturus’ investigational COVID-19 vaccines, for sale and use within V...
Arcturus will receive $40 million upfront payment and potential royalties based on vaccines produced Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on...
Arcturus Therapeutics (ARCT) announces that the company has received approval from the UK Health Research Authority to initiate a Phase 2 study for ARCT-810, a novel mRNA-based therapeutic candidate for Ornithine Transcarbamylase ((OTC)) Deficiency.OTC deficiency is a serious urea cycle disor...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare di...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...